BIVI vs. NRBO, KALA, SYBX, TCRT, LUMO, ORGS, COCP, MEIP, INDP, and SLGL
Should you be buying BioVie stock or one of its competitors? The main competitors of BioVie include NeuroBo Pharmaceuticals (NRBO), KALA BIO (KALA), Synlogic (SYBX), Alaunos Therapeutics (TCRT), Lumos Pharma (LUMO), Orgenesis (ORGS), Cocrystal Pharma (COCP), MEI Pharma (MEIP), Indaptus Therapeutics (INDP), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical preparations" industry.
NeuroBo Pharmaceuticals (NASDAQ:NRBO) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, community ranking, media sentiment, earnings, dividends and risk.
1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 0.5% of NeuroBo Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
NeuroBo Pharmaceuticals has a beta of -0.23, meaning that its stock price is 123% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
BioVie's return on equity of -90.22% beat NeuroBo Pharmaceuticals' return on equity.
NeuroBo Pharmaceuticals received 11 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 75.00% of users gave NeuroBo Pharmaceuticals an outperform vote while only 64.00% of users gave BioVie an outperform vote.
In the previous week, NeuroBo Pharmaceuticals and NeuroBo Pharmaceuticals both had 4 articles in the media. NeuroBo Pharmaceuticals' average media sentiment score of 0.77 beat BioVie's score of -0.15 indicating that BioVie is being referred to more favorably in the news media.
NeuroBo Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 117.39%. BioVie has a consensus price target of $8.00, suggesting a potential upside of 1,503.53%. Given NeuroBo Pharmaceuticals' higher possible upside, analysts clearly believe BioVie is more favorable than NeuroBo Pharmaceuticals.
Summary
NeuroBo Pharmaceuticals beats BioVie on 6 of the 11 factors compared between the two stocks.
Get BioVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
